Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cardiac biomarkers refine antihypertensive drug initiation decisions

Key clinical point: Incorporating hs-cTn and NT-proBNP into risk assessment for the decision to initiate antihypertensive pharmacotherapy can tip the balance.

Major finding: A modestly elevated cardiac biomarker level in patients with high blood pressure who would not be recommended for initiation of antihypertensive pharmacotherapy under current guidelines bumps them up into a risk level warranting treatment.

Study details: This was a study of 10-year cardiovascular disease event rates in 12,987 participants in three major U.S. cohort studies: ARIC, MESA, and the Dallas Heart Study.

Disclosures: The presenter reported having no financial conflicts of interest.

Citation:

Pandey A. AHA 2019 Abstract EP.AOS.521.141